Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Scalop Trial Logo

The first patient has now been randomised to the SCALOP-2 trial, a multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer.

Similar stories

The IMPROVE Trial team awarded inaugural Lelia Duley Prize for Patient-centred CLL Research

The IMPROVE trial team and scientific research group have just been awarded the inaugural Lelia Duley Prize for Patient-centred Chronic Lymphocytic Leukaemia Research.

NIHR fellowship to support national trial evaluating rehabilitation after kneecap dislocation

Dr Colin Forde has been awarded a National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Postdoctoral Award to lead a national study evaluating rehabilitation for people with a kneecap (patellar) dislocation.

Professor Laura Coates appointed Director of OCTRU

Professor Laura Coates has been appointed Director of the Oxford Clinical Trials Research Unit (OCTRU), where she will lead the next phase of its development and strengthen its position as a leading clinical trials unit.

NDORMS researchers win prestigious national leadership prizes

Professor of Orthopaedic Trauma Matthew Costa and NIHR Doctoral Research Fellow Rachel Kuo were announced among the winners of the NIHR20 Research Leaders Prizes in recognition of their outstanding contribution to health and care research.